Halozyme Therapeutics, Inc. provided revenue guidance for the fiscal year 2023. For the period, the company expected total revenue of $815 million to $845 million, representing growth of greater than 20% over 2022 expected total revenue.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
52.13 USD | +1.13% |
|
+4.14% | +39.48% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.48% | 6.56B | |
+15.19% | 121B | |
+19.91% | 114B | |
+19.07% | 23.61B | |
-19.80% | 20.43B | |
-15.73% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2023